Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Authors
Caramori, GaetanoRuggeri, Paolo
Di Stefano, Antonino
Mumby, Sharon
Girbino, Giuseppe
Adcock, Ian
Kirkham, Paul
Issue Date
2017-11-08
Metadata
Show full item recordAbstract
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. Long term cigarette smoking is the cause of more than 90% of COPD in Westernized countries. However, only a fraction of chronic heavy smokers develop symptomatic COPD by the age of 80 years. COPD is characterized by an abnormal immune response in the lower airways and its progression is associated with infiltration of the lung by innate and adaptive inflammatory immune cells that form lymphoid follicles. There is growing evidence that both cellular- and antibody-mediated autoimmunity has a fundamental role in the pathogenesis of stable COPD. In particular, carbonyl-modified proteins may help to drive autoimmunity in COPD and to cause the characteristic small airways abnormalities and even contribute to the pathogenesis of pulmonary emphysema. Although direct, indirect, and circumstantial evidence of a role for autoimmunity in stable COPD patients has been identified, no cause-and-effect relationship between autoimmunity and the mechanisms of COPD has been firmly established in man. As such the potential contribution of an autoimmune response to the pathogenesis of COPD exacerbation is still being investigated and represents an area of active research. Many drugs targeting autoimmune responses are already available and the results of controlled clinical trials are awaited with great interest. The potential for measuring specific serum autoantibodies as biomarkers to predict clinical phenotypes or progression of stable COPD is promising.Citation
Caramori G., Ruggeri P., Di Stefano A., Mumby S., et al (2017) 'Autoimmunity and COPD: clinical implications', Chest, 153(6), pp. 1424-1431 doi: 10.1016/j.chest.2017.10.033Publisher
ElsevierJournal
ChestPubMed ID
29126842Additional Links
https://journal.chestnet.org/article/S0012-3692(17)33046-5/fulltextType
Journal articleLanguage
enDescription
This is an accepted manuscript of an article published by American College of Chest Physicians in Chest Journal on 07/11/2017, available online: https://doi.org/10.1016/j.chest.2017.10.033 The accepted version of the publication may differ from the final published version.ISSN
0012-3692ae974a485f413a2113503eed53cd6c53
10.1016/j.chest.2017.10.033
Scopus Count
Collections
The following licence applies to the copyright and re-use of this item:
- Creative Commons
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/
Related articles
- Serum Levels of Autoantibodies Against Extracellular Antigens and Neutrophil Granule Proteins Increase in Patients with COPD Compared to Non-COPD Smokers.
- Authors: Ma A, Wen L, Yin J, Hu Y, Yue X, Li J, Dong X, Gupta Y, Ludwig RJ, Krauss-Etschmann S, Riemekasten G, Petersen F, Yu X
- Issue date: 2020
- Antielastin B-cell and T-cell immunity in patients with chronic obstructive pulmonary disease.
- Authors: Rinaldi M, Lehouck A, Heulens N, Lavend'homme R, Carlier V, Saint-Remy JM, Decramer M, Gayan-Ramirez G, Janssens W
- Issue date: 2012 Aug
- Autoantibodies in Chronic Obstructive Pulmonary Disease.
- Authors: Wen L, Krauss-Etschmann S, Petersen F, Yu X
- Issue date: 2018
- B cells in chronic obstructive pulmonary disease: moving to center stage.
- Authors: Polverino F, Seys LJ, Bracke KR, Owen CA
- Issue date: 2016 Oct 1
- High levels of lung resident CD4+CD28null cells in COPD: implications of autoimmunity.
- Authors: Hoetzenecker K, Mitterbauer A, Guenova E, Schweiger T, Altmann P, Zimmermann M, Hofbauer H, Beer L, Klepetko W, Ankersmit HJ
- Issue date: 2013 Mar